全球诊断放射性同位素市场

到 2030 年，全球诊断放射性同位素市场规模将达到 56 亿美元

全球诊断放射性同位素市场规模预计在2024年为42亿美元，到2030年将达到56亿美元，在2024-2030年的分析期间内，复合年增长率为5.0%。Technetium-99m是本报告分析的细分市场之一，预计其复合年增长率为4.1%，到分析期结束时将达到13亿美元。铊-201细分市场的复合年增长率预计在分析期间为4.1%。

美国市场规模估计为 11 亿美元，中国市场预期复合年增长率为 7.7%

美国诊断放射性同位素市场规模预计2024年达到11亿美元。作为世界第二大经济体的中国，预计在2030年将达到11亿美元，在分析期内（2024-2030年）的复合年增长率为7.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为2.5%和4.9%。在欧洲，预计德国的复合年增长率为3.2%。

全球诊断放射性同位素市场—主要趋势与驱动因素摘要

为什么诊断放射性同位素对于现代医学影像至关重要？

诊断性放射性同位素在现代医疗保健中发挥着至关重要的作用，它使临床医生能够以高特异性和微创性的方式观察和评估器官、组织和细胞过程的功能。这些放射性同位素用于核子医学成像技术，例如正电子发射断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT)，提供传统成像方式（例如 CT 和 MRI）无法捕获的代谢和功能资讯。例如，在肿瘤学中，用于 FDG-PET 扫描的氟-18 等诊断性放射性同位素有助于识别恶性肿瘤、对癌症进行分期、监测治疗效果并检测早期復发。在心臟病学中，Technetium-99m 等同位素用于心肌灌注成像，以评估冠状动脉疾病和心臟功能。神经系统应用包括阿兹海默症、癫痫和帕金森氏症的成像，可以在结构异常出现之前很久就识别出分子变化。诊断放射性同位素因其能够即时洞察生理功能而备受推崇，这对于早期发现和精准治疗计划至关重要。随着个人化医疗的日益普及，这些药物越来越多地与标靶治疗治疗相结合，构成了将诊断和治疗监测整合在一个连续体中的诊疗方法的基础。

科技进步如何提升基于放射性同位素的诊断能力？

快速的技术创新正在扩大医疗保健领域诊断放射性同位素的功效、安全性和范围。迴旋加速器和核子反应炉技术的发展提高了主要同位素的生产效率和可用性，解决了全球供应挑战并减少了对老化核子反应炉的依赖。混合 PET/CT 和 PET/MRI 扫描仪等成像硬体的增强实现了解剖数据和功能数据的融合，从而提高了诊断准确性并实现了更精确的疾病定位。软体主导的改进，包括人工智慧和先进的影像重建演算法，有助于减少扫描时间、辐射暴露和假阳性，同时提高影像解析度和量化能力。此外，放射性药物化学已经发展到可以设计同位素与高度特异性的生物标的（例如癌症生物标记和淀粉样斑块）结合的程度，从而实现高度灵敏、特异性疾病的成像诊断。使用放射性同位素标记示踪剂的伴随诊断技术正在与标靶治疗同步开发，透过为合适的患者提供合适的治疗，改善治疗效果并降低成本。放射性药物製备和品管的自动化使基于同位素的诊断更具可重复性和扩充性，从而实现更广泛的临床应用。这些技术进步正在推动基于放射性同位素的诊断策略朝更准确、个人化和高效的方向发展。

为什么全球医疗保健系统对放射性同位素成像的临床需求不断增加？

由于慢性病发病率上升、人口老化以及早期准确诊断的重要性日益提升，全球医疗保健系统对诊断用放射性同位素的临床需求激增。在肿瘤学领域，全球癌症发生率的快速增长推动了对正子断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 成像的需求，这些成像严重依赖放射性同位素进行肿瘤检测、分期和治疗监测。同样，心血管疾病盛行率的上升也推动了对铷-82 和铊-201 等同位素进行核应力测试和心肌灌注成像的需求。在神经病学领域，阿兹海默症和帕金森氏症等神经退化性疾病的发生率上升，正在扩大能够在分子层面上早期检测病理变化的放射性同位素的应用。此外，精准医疗和标靶治疗方法的广泛应用需要伴随诊断（通常涉及放射性同位素标记药物）来确认疾病的存在并预测治疗反应。随着小型移动成像系统和简化放射性通讯协定的发展，诊断放射性同位素也越来越多地被应用于门诊病人和流动医疗环境。在新兴市场，核子医学基础设施的改善和医疗保健支出的增加正在加速放射性同位素诊断的普及。随着临床医生和政策制定者重视及时、非侵入性和准确的诊断，预计未来几年放射性同位素的临床需求将大幅成长。

加速全球诊断放射性同位素市场成长的关键驱动因素是什么？

诊断放射性同位素市场的成长受到医疗、技术、监管和经济等多种因素的共同驱动，这些因素反映了分子影像在精准医疗中日益增长的作用。其中一个最重要的驱动因素是全球癌症、心血管疾病和神经退化性疾病负担的不断加重，早期准确的诊断可以显着改善患者的预后。此外，持续向基于价值的医疗保健模式转变，也鼓励医疗保健提供者采用能够更早指导治疗决策、减少不必要程序并优化治疗结果的诊断方法。迴旋加速器和放射性药物生产能力​​的扩张正在改善同位素的可及性，而对核子医学基础设施的持续投资正在开拓新的市场，尤其是在亚太地区和拉丁美洲。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构正在加速放射性药物的核准途径，尤其是那些作为新型疗法伴随诊断工具而开发的药物。此外，製药公司与诊断技术开发商之间的策略联盟正在推动治疗诊断学领域的发展，该领域使用放射性同位素进行标靶治疗的选择和监测。教育措施和临床培训计画也有助于缩小核医学人才缺口，进一步刺激招募。随着全球医疗保健系统走向早期疗育、降低医疗成本和个人化患者照护，诊断放射性同位素已成为下一代医疗图像影像和疾病管理的关键推动因素。

部分

放射性同位素类型（Technetium-99m、铕-201、镓-67、碘-123、FDG、铷-82、其他放射性同位素类型）、诊断放射性同位素（SPECT、PET、 β发射体）、用途（诊断、治疗）、最终用途（医院、专科诊所、诊断中心、学术用途/研究机构、其他最终用途）

受访公司范例（43家值得关注的公司）

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging SpA
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion（Canada）Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Diagnostic Radioisotopes Market to Reach US$5.6 Billion by 2030

The global market for Diagnostic Radioisotopes estimated at US$4.2 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Technetium-99m, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Thallium-201 segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.7% CAGR

The Diagnostic Radioisotopes market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Diagnostic Radioisotopes Market - Key Trends & Drivers Summarized

Why Are Diagnostic Radioisotopes Indispensable in Modern Medical Imaging?

Diagnostic radioisotopes play a critical role in contemporary healthcare by enabling clinicians to visualize and assess the function of organs, tissues, and cellular processes with high specificity and minimal invasiveness. These radioactive substances are used in nuclear medicine imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which provide metabolic and functional information that traditional imaging modalities like CT and MRI cannot capture. For example, in oncology, diagnostic radioisotopes like Fluorine-18 (used in FDG-PET scans) help identify malignant tumors, determine cancer staging, monitor treatment efficacy, and detect early recurrence. In cardiology, isotopes such as Technetium-99m are used in myocardial perfusion imaging to evaluate coronary artery disease and cardiac function. Neurological applications include imaging for Alzheimer’s disease, epilepsy, and Parkinson’s disease, where molecular changes can be identified long before structural anomalies appear. Diagnostic radioisotopes are prized for their ability to provide real-time insights into physiological function, which is crucial for early detection and precision treatment planning. As personalized medicine gains traction, these agents are increasingly used in tandem with targeted therapies, forming the foundation of theranostic approaches that combine diagnostics with treatment monitoring in a single continuum.

How Are Technological Advancements Enhancing the Capabilities of Radioisotope-Based Diagnostics?

Rapid technological innovations are expanding the efficacy, safety, and reach of diagnostic radioisotope applications in healthcare. Developments in cyclotron and reactor technologies have improved the production efficiency and availability of key isotopes, addressing global supply challenges and reducing reliance on aging nuclear reactors. Enhanced imaging hardware, such as hybrid PET/CT and PET/MRI scanners, now allows for the fusion of anatomical and functional data, yielding superior diagnostic accuracy and enabling more precise localization of disease. Software-driven improvements, including artificial intelligence and advanced image reconstruction algorithms, are helping reduce scan times, radiation exposure, and false positives while enhancing image resolution and quantification capabilities. Moreover, radiopharmaceutical chemistry has advanced to the point where isotopes can be engineered to bind to highly specific biological targets, such as cancer biomarkers or amyloid plaques, resulting in highly sensitive and disease-specific imaging. Companion diagnostics using radiolabeled tracers are being developed alongside targeted therapies to ensure the right patients receive the right treatment, improving therapeutic outcomes and reducing costs. Automation in radiopharmaceutical preparation and quality control is also making isotope-based diagnostics more reproducible and scalable for broader clinical use. These innovations are collectively driving a transition toward more precise, personalized, and efficient diagnostic strategies using radioisotopes.

Why Is Clinical Demand for Radioisotope Imaging Rising Across Global Healthcare Systems?

Clinical demand for diagnostic radioisotopes is rising sharply across healthcare systems worldwide due to the increasing burden of chronic diseases, aging populations, and the growing emphasis on early and accurate diagnosis. In oncology, the global surge in cancer incidence is fueling demand for PET and SPECT imaging, which rely heavily on radioisotopes for tumor detection, staging, and therapy monitoring. Similarly, the rising prevalence of cardiovascular diseases is driving the need for nuclear stress tests and myocardial perfusion imaging using isotopes like Rubidium-82 and Thallium-201. In neurology, the increase in neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases has led to greater utilization of radioisotopes that can detect early pathological changes at the molecular level. Furthermore, the widespread adoption of precision medicine and targeted therapy approaches necessitates companion diagnostics that often involve radiolabeled agents to confirm disease presence and predict treatment response. Diagnostic radioisotopes are also being increasingly integrated into outpatient and ambulatory settings due to the development of compact, mobile imaging systems and simplified radiotracer protocols. In emerging markets, improvements in nuclear medicine infrastructure and growing healthcare expenditure are accelerating the adoption of radioisotope diagnostics. With clinicians and policymakers placing more value on timely, non-invasive, and accurate diagnostics, the clinical demand for radioisotopes is expected to rise substantially over the coming years.

What Are the Key Drivers Accelerating Global Growth in the Diagnostic Radioisotopes Market?

The growth in the diagnostic radioisotopes market is driven by a convergence of medical, technological, regulatory, and economic factors that reflect the increasing role of molecular imaging in precision healthcare. One of the most important drivers is the rising global burden of cancer, cardiovascular disease, and neurodegenerative disorders-conditions for which early and accurate diagnosis dramatically improves patient outcomes. The continued shift toward value-based healthcare models is also pushing providers to adopt diagnostic methods that can inform treatment decisions early, reduce unnecessary procedures, and optimize therapeutic efficacy. Expansion in cyclotron and radiopharmaceutical production capabilities is improving isotope accessibility, while ongoing investment in nuclear medicine infrastructure, especially in Asia-Pacific and Latin America, is opening new markets. Regulatory agencies like the FDA and EMA are accelerating the approval pathways for radiopharmaceuticals, particularly those developed as companion diagnostics for novel therapeutics. Moreover, strategic collaborations between pharmaceutical companies and diagnostic developers are advancing the theranostics field, where radioisotopes are used to select and monitor targeted therapies. Educational initiatives and clinical training programs are also helping bridge the talent gap in nuclear medicine, further supporting adoption. As global health systems strive for earlier intervention, lower healthcare costs, and personalized patient care, diagnostic radioisotopes are positioned as a critical enabler of the next generation of medical imaging and disease management.

SCOPE OF STUDY:

The report analyzes the Diagnostic Radioisotopes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Radioisotope Type (Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, Other Radioisotope Types); Diagnostic Radioisotope (SPECT, PET, Beta Emitters); Application (Diagnostic, Therapeutic); End-Use (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Advanced Accelerator Applications
• Bayer AG
• Bracco Imaging S.p.A.
• BWX Technologies, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler AG
• GE HealthCare
• IBA Radiopharma Solutions
• Isotopia Molecular Imaging Ltd.
• Jubilant DraxImage Inc.
• Lantheus Holdings, Inc.
• Mallinckrodt Pharmaceuticals
• Nordion (Canada) Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• Orano Med LLC
• SHINE Technologies
• Siemens Healthineers AG
• Telix Pharmaceuticals Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Diagnostic Radioisotopes - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growth in Molecular Imaging and Nuclear Medicine Throws the Spotlight on Diagnostic Radioisotope Demand
  • Rising Prevalence of Cancer and Cardiac Disorders Fuels Use of SPECT and PET Tracers
  • Aging Infrastructure and Reactor Downtime Challenges Create Opportunities for Cyclotron-Based Isotope Production
  • Regulatory Approvals of New PET Tracers Accelerate Adoption in Oncology, Neurology, and Cardiology
  • Push for Personalized Imaging Protocols Spurs Use of Radiolabeled Biomarkers in Patient Stratification
  • Growth in Theranostics Fuels Convergence of Diagnostic and Therapeutic Isotopes in Hybrid Applications
  • Global Shortage of Molybdenum-99 Highlights Demand for Diversified Isotope Sourcing Strategies
  • Investment in Generator-Based Delivery Systems Supports On-Site Production for Smaller Facilities
  • Rise in Outpatient Nuclear Imaging Clinics Drives Use of Short Half-Life Isotopes with Quick Turnaround
  • Integration with AI and Quantitative Imaging Analytics Enhances Data Interpretation in Radioisotope Scans
  • Push for Low-Radiation Dose Imaging Accelerates Development of High-Specificity Tracers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diagnostic Radioisotopes Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diagnostic Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Technetium-99m by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Technetium-99m by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Thallium-201 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Thallium-201 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gallium-67 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Gallium-67 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Iodine-123 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Iodine-123 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for FDG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for FDG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Rubidium-82 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Rubidium-82 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Radioisotope Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Radioisotope Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for SPECT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for SPECT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for PET by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for PET by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Diagnostic Radioisotopes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Diagnostic Radioisotopes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Diagnostic Radioisotopes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Diagnostic Radioisotopes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Diagnostic Radioisotopes by Radioisotope Type - Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Diagnostic Radioisotopes by Radioisotope Type - Percentage Breakdown of Value Sales for Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82 and Other Radioisotope Types for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Diagnostic Radioisotopes by Diagnostic Radioisotope - Beta Emitters, SPECT and PET Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Diagnostic Radioisotopes by Diagnostic Radioisotope - Percentage Breakdown of Value Sales for Beta Emitters, SPECT and PET for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Diagnostic Radioisotopes by Application - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Diagnostic Radioisotopes by Application - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Diagnostic Radioisotopes by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Diagnostic Radioisotopes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION